Review article: novel oral-targeted therapies in inflammatory bowel disease

Research output: Contribution to journalArticlepeer-review

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{eff70d247ef54843be35af83691d4abf,
title = "Review article: novel oral-targeted therapies in inflammatory bowel disease",
abstract = "SummaryBackground: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.Aims: To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management.Methods: Pubmed and Medline searches were performed up to 1 March 2018using keywords: “IBD”, “UC”, “CD”, “inflammatory bowel disease” “ulcerative colitis”, “Crohn{\textquoteright}s disease” in combination with “phase”, “study”, “trial” and “oral”. A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted.Results: In randomised controlled trials primary efficacy endpoints were met fortofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM-300 (a4-integrin antagonist-phase II) in ulcerative colitis. Ozanimod (S1P 4 receptor agonist-phase II) also demonstrated clinical remission. For Crohn{\textquoteright}s disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone- 3-carboxide small molecule-phase II) was also efficacious. Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted.Conclusions: This is potentially the start of an exciting new era in which multipletherapeutic options are at the disposal of physicians to treat IBD on an individualised basis. Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible.",
author = "Subrata Ghosh and Marietta Iacucci",
year = "2018",
month = apr,
day = "19",
doi = "10.1111/apt.14669",
language = "English",
journal = "Alimentary Pharmacology & Therapeutics",
issn = "0269-2813",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Review article: novel oral-targeted therapies in inflammatory bowel disease

AU - Ghosh, Subrata

AU - Iacucci, Marietta

PY - 2018/4/19

Y1 - 2018/4/19

N2 - SummaryBackground: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.Aims: To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management.Methods: Pubmed and Medline searches were performed up to 1 March 2018using keywords: “IBD”, “UC”, “CD”, “inflammatory bowel disease” “ulcerative colitis”, “Crohn’s disease” in combination with “phase”, “study”, “trial” and “oral”. A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted.Results: In randomised controlled trials primary efficacy endpoints were met fortofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM-300 (a4-integrin antagonist-phase II) in ulcerative colitis. Ozanimod (S1P 4 receptor agonist-phase II) also demonstrated clinical remission. For Crohn’s disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone- 3-carboxide small molecule-phase II) was also efficacious. Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted.Conclusions: This is potentially the start of an exciting new era in which multipletherapeutic options are at the disposal of physicians to treat IBD on an individualised basis. Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible.

AB - SummaryBackground: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.Aims: To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management.Methods: Pubmed and Medline searches were performed up to 1 March 2018using keywords: “IBD”, “UC”, “CD”, “inflammatory bowel disease” “ulcerative colitis”, “Crohn’s disease” in combination with “phase”, “study”, “trial” and “oral”. A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted.Results: In randomised controlled trials primary efficacy endpoints were met fortofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM-300 (a4-integrin antagonist-phase II) in ulcerative colitis. Ozanimod (S1P 4 receptor agonist-phase II) also demonstrated clinical remission. For Crohn’s disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone- 3-carboxide small molecule-phase II) was also efficacious. Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted.Conclusions: This is potentially the start of an exciting new era in which multipletherapeutic options are at the disposal of physicians to treat IBD on an individualised basis. Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible.

U2 - 10.1111/apt.14669

DO - 10.1111/apt.14669

M3 - Article

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

SN - 0269-2813

ER -